B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Maria Stefania Infante; Jon Salmanton-García; Ana Fernández-Cruz; Francesco Marchesi; Ozren Jaksic; Barbora Weinbergerová; Caroline Besson; Rafael F Duarte; Federico Itri; Toni Valković; Tomáš Szotkovski; Alessandro Busca; Anna Guidetti; Andreas Glenthøj; Graham P Collins; Valentina Bonuomo; Uluhan Sili; Guldane Cengiz Seval; Marina Machado; Raul Cordoba; Ola Blennow; Ghaith Abu-Zeinah; Sylvain Lamure; Austin Kulasekararaj; Iker Falces-Romero; Chiara Cattaneo; Jaap van Doesum; Klára Piukovics; Ali S Omrani; Gabriele Magliano; Marie-Pierre Ledoux; Cristina de Ramon; Alba Cabirta; Luisa Verga; Alberto López-García; Maria Gomes da Silva; Zlate Stojanoski; Stef Meers; Tobias Lahmer; Sonia Martín-Pérez; Julio Dávila-Vals; Jens van Praet; Michail Samarkos; Yavuz M Bilgin; Linda Katharina Karlsson; Josip Batinić; Anna Nordlander; Martin Schönlein; Martin Hoenigl; Zdeněk Ráčil; Miloš Mladenović; Michaela Hanakova; Giovanni Paolo Maria Zambrotta; Nick de Jonge; Tatjana Adžić-Vukičević; Raquel Nunes-Rodrigues; Lucia Prezioso; Milan Navrátil; Monia Marchetti; Annarosa Cuccaro; Maria Calbacho; Antonio Giordano; Oliver A Cornely; José-Ángel Hernández-Rivas; Livio Pagano

doi:10.3389/fonc.2022.992137

Back

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Journal article

Open access

Peer reviewed

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, Francesco Marchesi, Ozren Jaksic, Barbora Weinbergerová, Caroline Besson, Rafael F Duarte, Federico Itri, Toni Valković, …

Frontiers in Oncology, Vol.12

04/10/2022

DOI: https://doi.org/10.3389/fonc.2022.992137

Abstract

SARS-CoV-2

Chronic lymphocytic leukemia (CLL)

Immune system COVID-19

Infection risk

Lymphoproliferative diseases (LPD)

Non-Hodgkin lymphoma (NHL)

Targeted drugs

COVID-19

Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.3389/fonc.2022.992137View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Creators - without role: Maria Stefania Infante - Hospital Universitario Infanta Leonor
Jon Salmanton-García - Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases
Ana Fernández-Cruz - Hospital Universitario Puerta de Hierro Majadahonda
Francesco Marchesi - Istituti di Ricovero e Cura a Carattere Scientifico
Ozren Jaksic - University Hospital Dubrava
Barbora Weinbergerová - Masaryk University
Caroline Besson - Centre Hospitalier de Versailles
Rafael F Duarte - Hospital Universitario Puerta de Hierro Majadahonda
Federico Itri - Ospedale San Luigi Gonzaga
Toni Valković - University of Rijeka
Tomáš Szotkovski - University Hospital Olomouc
Alessandro Busca - Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Anna Guidetti - Fondazione IRCCS Istituto Nazionale dei Tumori
Andreas Glenthøj - Copenhagen University Hospital
Graham P Collins - Churchill Hospital
Valentina Bonuomo - University of Verona
Uluhan Sili - Karolinska University Hospital
Guldane Cengiz Seval - Ankara University
Marina Machado - Hospital General Universitario Gregorio Marañón
Raul Cordoba - Hospital Universitario Fundación Jiménez Díaz
Ola Blennow - Karolinska University Hospital
Ghaith Abu-Zeinah - Cornell University
Sylvain Lamure - Université de Montpellier
Sylvain Lamure - Université de Montpellier
Austin Kulasekararaj - King's College Hospital
Iker Falces-Romero - Hospital Universitario La Paz
Chiara Cattaneo - Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Jaap van Doesum - University Medical Center Groningen
Klára Piukovics - University of Szeged
Ali S Omrani - Hamad Medical Corporation
Gabriele Magliano - Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Marie-Pierre Ledoux - Institut de Cancérologie de Strasbourg Europe
Cristina de Ramon - Complejo Hospitalario de Salamanca
Alba Cabirta - Vall d'Hebron Hospital Universitari
Luisa Verga - Azienda Ospedaliera San Gerardo
Alberto López-García - Hospital Universitario Fundación Jiménez Díaz
Maria Gomes da Silva - Instituto Português de Oncologia Francisco Gentil
Zlate Stojanoski - PHI University Psychiatric Clinic - Skopje
Stef Meers - AZ Klina
Tobias Lahmer - Klinikum rechts der Isar
Sonia Martín-Pérez - Hospital Nuestra Señora de Alarcos
Julio Dávila-Vals - Hospital Nuestra Señora de Alarcos
Jens van Praet - AZ Sint-Jan
Michail Samarkos - Laiko General Hospital of Athens
Yavuz M Bilgin - Admiraal De Ruyter Ziekenhuis
Linda Katharina Karlsson - Copenhagen University Hospital
Josip Batinić - University Hospital Centre Zagreb
Anna Nordlander - Karolinska University Hospital
Martin Schönlein - University Medical Center Hamburg-Eppendorf
Martin Hoenigl - Medical University of Graz
Zdeněk Ráčil - Institute of Haematology and Blood Transfusion
Miloš Mladenović - COVID Hospital "Batajnica" (Belgrade)
Michaela Hanakova - Institute of Haematology and Blood Transfusion
Giovanni Paolo Maria Zambrotta - University of Milano-Bicocca
Nick de Jonge - Amsterdam University Medical Centers
Tatjana Adžić-Vukičević - COVID Hospital "Batajnica" (Belgrade)
Raquel Nunes-Rodrigues - IPO Porto
Lucia Prezioso - Ospedale Maggiore
Milan Navrátil - University Hospital Ostrava
Monia Marchetti - Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
Annarosa Cuccaro - Azienda Usl Toscana Centro
Maria Calbacho - Hospital Universitario 12 De Octubre
Antonio Giordano - Università Cattolica del Sacro Cuore
Oliver A Cornely - University Hospital Cologne
José-Ángel Hernández-Rivas - Hospital Universitario Infanta Leonor
Livio Pagano - Università Cattolica del Sacro Cuore
Publication Details: Frontiers in Oncology, Vol.12
Identifiers: 9939451709311
Academic Unit: Institut de Génétique Moléculaire de Montpellier - IGMM
Language: English
Resource Type: Journal article
Local Fields: hal-04427149